A Phase IV, Open Label, Multi-center Study to Assess the Effect of Intravitreal Injections of Macugen (Pegaptanib Sodium Injection)Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium.

Trial Profile

A Phase IV, Open Label, Multi-center Study to Assess the Effect of Intravitreal Injections of Macugen (Pegaptanib Sodium Injection)Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Pegaptanib (Primary)
  • Indications Age-related macular degeneration; Diabetic macular oedema; Retinal vein occlusion
  • Focus Therapeutic Use
  • Sponsors Valeant Pharmaceuticals International
  • Most Recent Events

    • 25 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2018.
    • 25 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 May 2018.
    • 02 Jun 2015 Planned End Date changed from 1 Mar 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top